Gabriel Lemieux

Gabriel Lemieux

Auto-generated profile, based on publicly available information

Gabriel Lemieux

Université de Sherbrooke

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Antiviral Research
Verified
Journal Article
Open access
JPJimena Pérez-Vargas
Jimena Pérez-Vargas
GLGabriel Lemieux
Gabriel Lemieux
CTConnor A.H. Thompson
Connor A.H. Thompson
ADAntoine Désilets
Antoine Désilets
SESiobhan Ennis
Siobhan Ennis
FJFrançois Jean
François Jean
SARS-CoV-2 Omicron subvariants with increased transmissibility and immune evasion are spreading globally with alarming persistence. Whether the mutations and evolution of spike (S) Omicron subvariants alter the viral hijacking of human TMPRSS2 for viral entry remains to be elucidated. This is particularly important to investigate because of the large number and diversity of mutations of S Omicron subvariants reported since the emergence of BA.1. Here we report that human TMPRSS2 is a molecular determinant of viral entry for all the Omicron clinical isolates tested in human lung cells, including ancestral Omicron subvariants (BA.1, BA.2, BA.5), contemporary Omicron subvariants (BQ.1.1, XBB.1.5, EG.5.1) and currently circulating Omicron BA.2.86. First, we used a co-transfection assay to demonstrate the endoproteolytic cleavage by TMPRSS2 of spike Omicron subvariants. Second, we found that N-0385, a highly potent TMPRSS2 inhibitor, is a robust entry inhibitor of virus-like particles harbouring the S protein of Omicron subvariants. Third, we show that N-0385 exhibits nanomolar broad-spectrum antiviral activity against live Omicron subvariants in human Calu-3 lung cells and primary patient-derived bronchial epithelial cells. Interestingly, we found that N-0385 is 10-20 times more potent than the repositioned TMPRSS2 inhibitor, camostat, against BA.5, EG.5.1, and BA.2.86. We further found that N-0385 shows broad synergistic activity with clinically approved direct-acting antivirals (DAAs), i.e., remdesivir and nirmatrelvir, against Omicron subvariants, demonstrating the potential therapeutic benefits of a multi-targeted treatment based on N-0385 and DAAs.

31 October 2023 in ChemMedChem
Verified
Journal Article
Open access
ÉCÉloïc Colombo
Éloïc Colombo
ADAntoine Désilets
Antoine Désilets
MHMalihe Hassanzadeh
Malihe Hassanzadeh
GLGabriel Lemieux
Gabriel Lemieux
IMIsabelle Marois
Isabelle Marois
PBPierre-Luc Boudreault
Pierre-Luc Boudreault
Human influenza viruses cause acute respiratory symptoms that can lead to death. Due to the emergence of antiviral drug‐resistant strains, there is an urgent requirement for novel antiviral agents and innovative therapeutic strategies. Using the peptidomimetic ketobenzothiazole protease inhibitor RQAR‐Kbt (IN‐1, aka N‐0100) as a starting point, we report how substituting P2 and P4 positions with natural and unnatural amino acids can modulate the inhibition potency toward matriptase, a prototypical type II transmembrane serine protease (TTSP) that acts as a priming protease for influenza viruses. We also introduced modifications of the peptidomimetics N‐terminal groups, leading to significant improvements (from μM to nM, 60 times more potent than IN‐1) in their ability to inhibit the replication of influenza H1N1 virus in the Calu‐3 cell line derived from human lungs. The selectivity towards other proteases has been evaluated and explained using molecular modeling with a crystal structure recently obtained by our group. By targeting host cell TTSPs as a therapeutic approach, it may be possible to overcome the high mutational rate of influenza viruses and consequently prevent potential drug resistance.

31 March 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
GLGabriel Lemieux
Gabriel Lemieux
JPJimena Pérez-Vargas
Jimena Pérez-Vargas
ADAntoine Désilets
Antoine Désilets
MHMalihe Hassanzadeh
Malihe Hassanzadeh
CTConnor A. H. Thompson
Connor A. H. Thompson
PBPierre-Luc Boudreault
Pierre-Luc Boudreault
The worldwide spread of new SARS-CoV-2 variants emphasizes the need to diversify existing therapeutic strategies. TMPRSS2, a host protease crucial for SARS-CoV-2 entry, has garnered significant research attention as a potential target for therapeutic intervention. Here, we optimized N-0385, a previously reported TMPRSS2 ketobenzothiazole-based peptidomimetic inhibitor, by screening 135 derivatives for target affinity and antiviral potency. Among the top candidates, N-0695 exhibited low nanomolar Ki values against three TTSPs associated with respiratory virus entry: TMPRSS2, matriptase, and TMPRSS13. Notably, N-0920 demonstrated exceptional potency in reducing SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, representing the first in cellulo picomolar inhibitor with EC50 values of 300 and 90 pM, respectively. Additionally, molecular modeling provided insights into the binding interactions between the compounds and their targets. This study underscores the effectiveness of our screening approach in refining an existing peptidomimetic scaffold to enhance selectivity and antiviral activity.

19 July 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MDMichael Desgagné
Michael Desgagné
ADAntoine Désilets
Antoine Désilets
SFSára Ferková
Sára Ferková
MLMatthieu Lepage
Matthieu Lepage
OPOlivier Perreault
Olivier Perreault
PBPierre-Luc Boudreault
Pierre-Luc Boudreault
TMPRSS6 is a potential therapeutic target for the treatment of iron overload due to its role in regulating levels of hepcidin. Although potent TMPRSS6 inhibitors have been previously developed, their lack of specificity requires optimization to avoid potential side effects before pursuing preclinical development with in vivo models. Here, using computer-aided drug design based on a TMPRSS6 homology model, we reveal that the S2 position of TMPRSS6 offers a potential avenue to achieve selectivity against other members of the TTSP family. Accordingly, we synthesized novel peptidomimetic molecules containing lipophilic amino acids at the P2 position to exploit this unexplored pocket. This enabled us to identify TMPRSS6-selective small molecules with low nanomolar affinity. Finally, pharmacokinetic parameters were determined, and a compound was found to be potent in cellulo toward its primary target while retaining TTSP-subtype selectivity and showing no signs of alteration in in vitro TEER experiments.

31 August 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SDSébastien P. Dion
Sébastien P. Dion
ADAntoine Désilets
Antoine Désilets
GLGabriel Lemieux
Gabriel Lemieux
RLRichard Leduc
Richard Leduc
TMPRSS6 is a type II transmembrane serine protease involved in iron homeostasis expressed as 4 isoforms in humans. TMPRSS6 isoform 2 downregulates hepcidin production by cleaving hemojuvelin and other surface proteins of hepatocytes. The functions of catalytically impaired isoforms 3 and 4 are still unknown. Here we demonstrate that TMPRSS6 isoforms 3 and 4 reduce the proteolytic activity of isoform 2 and uncover the ability of isoforms to interact. Moreover, we identified 49 potential protein partners common to TMPRSS6 isoforms, including TfR1, known to be involved in iron regulation. By co-expressing TMPRSS6 and TfR1, we show that TfR1 is cleaved and shed from the cell surface. Further, we demonstrate that TMPRSS6 isoforms 3 and 4 behave as dominant negative.

29 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AJAlexandre Joushomme
Alexandre Joushomme
ADAntoine Désilets
Antoine Désilets
WCWilliam Champagne
William Champagne
MHMalihe Hassanzadeh
Malihe Hassanzadeh
GLGabriel Lemieux
Gabriel Lemieux
RLRichard Leduc
Richard Leduc
TMPRSS13, a member of the Type II Transmembrane Serine Proteases (TTSP) family, is involved in cancer progression and in cell entry of respiratory viruses. To date, no inhibitors have been specifically developed toward this protease. In this study, a chemical library of 65 ketobenzothiazole-based peptidomimetic molecules was screened against a proteolytically active form of recombinant TMPRSS13 to identify novel inhibitors. Following an initial round of screening, subsequent synthesis of additional derivatives supported by molecular modelling, uncovered important molecular determinants involved in TMPRSS13 inhibition. One inhibitor, N-0430, achieved low nanomolar affinity towards TMPRSS13 activity in a cellular context. Using a SARS-CoV-2 pseudovirus cell entry model, we further show the ability of N-0430 to block TMPRSS13-dependent entry of the pseudovirus. The identified peptidomimetic inhibitors and the molecular insights of their potency gained from this study will aid in the development of specific TMPRSS13 inhibitors.